|Awarded On||August 21, 2019|
|Title||Chemoprevention of acquired therapeutic resistance and disease recurrence in ovarian cancer|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||Texas Tech University Health Sciences Center|
|Principal Investigator/Program Director||Komaraiah Palle|
*Pending contract negotiation
Ovarian cancer (OC) is the second leading cause of deaths related to gynecologic cancers in US women. Advances in surgery and chemotherapy have not significantly changed the overall survival rate of OC patients for the last few decades, which highlights the need for new therapeutics. Even though most patients initially respond to platinum drugs based chemotherapy, about 80% of the cases relapse, develop platinum resistance and die with the advanced disease. Therefore, it is vital to understand the molecular mechanisms contributing to platinum resistance and disease recurrence in OC. In a paradigm-shift, our studies discovered Rad6 protein upregulation and poor survival of OC patients. Rad6 r...